Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 6/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 6/20 | 0.49 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023238 | 0.94 | CNR1 (0.51) | CYP1A2CYP2D6CNR1PAK1MAP3K5 | |
| SCHEMBL4016285 | 0.93 | CNR1 (0.58) | CYP1A2CYP2D6CNR1PAK1MAP3K5 | |
| SCHEMBL4022769 | 0.91 | CYP1A2 (0.55) | CYP1A2CYP2D6CNR1PAK1MAP3K5 | |
| SCHEMBL4018106 | 0.91 | CNR1 (0.58) | CYP1A2CYP2D6CNR1PAK1MAP3K5 | |
| SCHEMBL4023244 | 0.90 | CNR1 (0.57) | CYP1A2CYP2D6CNR1PAK1MAP3K5 | |
| SCHEMBL4019280 | 0.89 | CYP1A2 (0.54) | CYP1A2CYP2D6CNR1PAK1MAP3K5 | |
| SCHEMBL4017884 | 0.88 | PAK1 (0.63) | CYP1A2CYP2D6CNR1PAK1AKT1 | |
| SCHEMBL4021683 | 0.87 | CYP1A2 (0.55) | CYP1A2CYP2D6CNR1PAK1MAP3K5 | |
| SCHEMBL4018993 | 0.87 | CYP1A2 (0.53) | CYP1A2CYP2D6CNR1PAK1MAP3K5 | |
| SCHEMBL4023489 | 0.86 | CYP1A2 (0.56) | CYP1A2CYP2D6CNR1PAK1MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | claimed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | claimed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | PTGER2, PTGER1, PTGDR2 | CYP1A2 72/4885CYP2D6 302/4885CNR1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.